Gene expression of glucocorticoid receptor α and β in giant cell tumour of bone: Evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells

Molecular and Cellular Endocrinology

Volumn 181, Issue 1-2, 2001, Pages 199-206

  Huang, Lin ^a,b   Xu, Jiake ^a   Kumta, Shekhar M ^b   Zheng, Ming H ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Giant cell tumour of bone (GCT); Glucocorticoid receptor; Osteoclastogenesis; Osteoprotegerin (OPG); Receptor activator of NF B ligand (RANKL)

Indexed keywords

CALCITRIOL; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR SUBTYPE;

ARTICLE; CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MACROPHAGE; MESENCHYME CELL; MULTINUCLEAR CELL; OSTEOCLASTOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; TUMOR CELL LINE;

CELLS, CULTURED; DEXAMETHASONE; GENE EXPRESSION REGULATION, NEOPLASTIC; GIANT CELL TUMOR OF BONE; GLUCOCORTICOIDS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; OSTEOCLASTS; OSTEOGENESIS; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 0035811548     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(01)00486-5     Document Type: Article

References (43)

1. An immunohistological study of giant cell tumour of bone: Evidence for an osteoclast origin of the giant cells
2. Glucocorticoid Receptor b, a potential endogenous inhibitor of glucocorticoid action in humans
3. Histomophometric profile, pathophysiology and reversibility of glucocorticoid-induced osteoporosis
4. Osteoclasts from human giant cell tumours of bone lack estrogen receptors
5. Differential effects of glucocorticoids on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones
6. Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumours
7. Differential effect of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats
8. Perspectives: Bone histomorphometry in glucocorticoid-induced osteoporosis
9. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis
10. The genomic structure of the human glucocorticoid receptor
11. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
12. Human giant cell tumours of bone: Identification and characterisation of cell types
13. New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumours of bone
14. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
15. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
16. Tumour necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
17. Gene expression of osteoprotegerin ligand, osteoprotegerin and receptor activator of NF-κB in giant cell tumour of bone: Possible involvement in tumour cell-induced osteoclast-like cell formation
18. Detection of estrogen receptor a, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNA imputative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in-situ hybridisation
19. Purification and characterization of fully functional human osteoclast precursors
20. Promoter structure of mouse RANKL/TRANCE/ OPGL/ODF gene
21. Tumour necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
22. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis
23. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
24. Serum blocks the osteolytic effect of cortisol in neonatal mouse calvaria
25. Glucocorticoid-induced osteoporosis
26. New developments in the pathogenesis and treatment of steroid-induced osteoporosis
27. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
28. The human glucocorticoid receptor β isoform. Expression, biochemical properties and putative function
29. Absence of glucocorticoid receptor-beta in mice
30. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
31. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
32. Modulation of osteoclast differentiation
33. Modulation of osteoclast differentiation and function by the new members of the tumour necrosis factor receptor and ligand families
34. Glucocorticoids impair bone resorptive ability and viability of osteoclasts disaggregated from neonatal rat long bones
35. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
36. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in co-cultures with mouse spleen cells
37. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids
38. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kB ligand
39. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRNACE/RANKL
40. Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in-situ hybridisation
41. Gene expression of transforming growth factor b and its type II receptor in giant cell tumours of bone: Possible involvement in osteoclast-like cell migration
42. The recruitment of CD68+ mononuclear cells in giant cell tumour of bone is associated with the production of monocyte chemoattractant protein-1
43. Telomeric fusion is a major cytogenetic aberration of spindle-shaped mononuclear cells derived from giant cell tumours of bone